Bleomycin-Induced Lung Injury

Overview

Request a Study Outline from IPST

The progression of fibrosis may lead to respiratory failure combined with pulmonary arterial hypertension, giving a poor prognosis in patients with various types of interstitial lung disorders.

Bleomycin (BLM) is a glycopeptide antibiotic commonly used as an anticancer agent. It is widely used in research for its association with development of pulmonary fibrosis in animals which has great similarities with histological and functional fibrotic lung disease in humans.

This study model investigates the functional, anatomical, and biochemical consequences of the onset of BLM-induced lung fibrosis, as well as the full range of changes resulting from any test compound treatment.